Orlistat  reduced body weight ( weighted mean difference : −2.12 , p < 0.001 ) , total‐cholesterol ( weighted mean difference : −0.30 mmol/L , p < 0.001 ) , low‐density lipoprotein cholesterol ( weighted mean difference : −0.27 mmol/L , p < 0.001 ) , high‐density lipoprotein cholesterol ( weighted mean difference : −0.034 mmol/L , p < 0.001 ) and triglyceride ( weighted mean difference : −0.09 mmol/L , p < 0.001 ) concentrations , while no effect on lipoprotein(a ) was observed .
Total‐ and low‐density lipoprotein cholesterol‐lowering were associated negatively with duration of orlistat treatment and positively with body weight changes .
In conclusion , Orlistat treatment slightly reduces cholesterol and triglyceride levels , but not lipoprotein(a ) levels .
Total‐ and low‐density lipoprotein cholesterol levels reductions are more consistent in patients with greater body weight reduction and shorter duration of orlistat treatment .
We investigated the efficacy of orlistat on plasma lipids and body weight in a meta‐ analysis of 33 studies including 9732  participants .Orlistat  was associated with a slight but significant decrease in body weight , plasma cholesterol and triglyceride concentrations , whereas plasma Lp(a ) levels were not affected by orlistat treatment .
Greater body weight reduction and lower duration of orlistat treatment promoted more consistent plasma total‐ and LDL‐cholesterol lowering
& NA ; Orlistat , an inhibitor of intestinal lipase , promotes body weight reduction .
The lipid‐lowering efficacy of orlistat is controversial and the effect of orlistat‐induced body weight reduction on lipid changes has not been explored in meta‐regression analyses .
HighlightsOrlistat is an inhibitor of intestinal lipase promoting body weight reduction , but whose lipid‐lowering efficacy is controversial .
Orlistat is as beneficial as metformin in the treatment of polycystic ovarian syndrome.
The objective of this study was to evaluate and compare the effect of treatment with orlistat vs. metformin on the hormonal and biochemical features of patients with polycystic ovarian syndrome ( PCOS ) . Twenty-one Caucasian women with PCOS [ mean ( + /-SEM ) age 27 + /- 0.9 yr and body mass index 36.7 + /- 3.3 kg/m(2 ) ] participated in this prospect i ve , r and omized , open-labeled study . All subjects had an 8-wk run-in period of dietary modification and then r and omized to receive either metformin ( 500 mg three times daily ) or orlistat ( 120 mg three times daily ) for 3 months . Weight , blood pressure , and fasting blood sample s were taken at screening , r and omization , and on completion . Insulin resistance ( IR ) was calculated using the homeostasis model of assessment (HOMA)-IR method [ HOMA-IR = ( insulin x glucose)/22.5 ] . The results are expressed as mean + /- SEM . When compared with baseline , treatment with both orlistat [ 93.5 + /- 11.5 ng/dl ( 3.24 + /- 0.4 nmol/liter ) vs. 114.5 + /- 11.5 ng/dl ( 3.97 + /- 0.4 nmol/liter ) , P = 0.039 ] and metformin [ 97.2 + /- 11.5 ng/dl ( 3.37 + /- 0.4 nmol/liter ) vs. 120.0 + /- 8.7 ng/dl ( 4.16 + /- 0.3 nmol/liter ) , P = 0.048 ] produced a significant reduction in total testosterone . Treatment with orlistat produced a 4.69 % reduction in weight ( 99.0 + /- 6.0 vs. 94.6 + /- 6.1 kg , P = 0.002 ) , and this reduction was more significant than the reduction produced by metformin ( 4.69 vs. 1.02 % , P = 0.006 ) . There was no significant reduction seen after either treatment group for fasting insulin , HOMA-IR , SHBG , or any of the lipid parameters studied . In this study , orlistat produced a significant reduction in weight and total testosterone . The reduction in total testosterone was similar to that seen after treatment with metformin . Therefore , orlistat may prove to be a useful adjunct in the treatment of PCOS
Orlistat  reduced body weight ( weighted mean difference : −2.12 , p < 0.001 ) , total‐cholesterol ( weighted mean difference : −0.30 mmol/L , p < 0.001 ) , low‐density lipoprotein cholesterol ( weighted mean difference : −0.27 mmol/L , p < 0.001 ) , high‐density lipoprotein cholesterol ( weighted mean difference : −0.034 mmol/L , p < 0.001 ) and triglyceride ( weighted mean difference : −0.09 mmol/L , p < 0.001 ) concentrations , while no effect on lipoprotein(a ) was observed .
Total‐ and low‐density lipoprotein cholesterol‐lowering were associated negatively with duration of orlistat treatment and positively with body weight changes .
In conclusion , Orlistat treatment slightly reduces cholesterol and triglyceride levels , but not lipoprotein(a ) levels .
Total‐ and low‐density lipoprotein cholesterol levels reductions are more consistent in patients with greater body weight reduction and shorter duration of orlistat treatment .
We investigated the efficacy of orlistat on plasma lipids and body weight in a meta‐ analysis of 33 studies including 9732  participants .Orlistat  was associated with a slight but significant decrease in body weight , plasma cholesterol and triglyceride concentrations , whereas plasma Lp(a ) levels were not affected by orlistat treatment .
Greater body weight reduction and lower duration of orlistat treatment promoted more consistent plasma total‐ and LDL‐cholesterol lowering
& NA ; Orlistat , an inhibitor of intestinal lipase , promotes body weight reduction .
The lipid‐lowering efficacy of orlistat is controversial and the effect of orlistat‐induced body weight reduction on lipid changes has not been explored in meta‐regression analyses .
HighlightsOrlistat is an inhibitor of intestinal lipase promoting body weight reduction , but whose lipid‐lowering efficacy is controversial .